Press Releases

Advanced Search
  • Oct 12, 2017
    - Emphasizes Robustness of its Technology Despite Financial Uncertainty -

    Biostage, Inc. (OTC-QB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...

  • Oct 6, 2017
    - Delisted from NASDAQ effective October 6, 2017 -

    Biostage, Inc. ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and...

  • Oct 2, 2017
    - Presentation with live video webcast Thursday, October 5th at 4:45PM PDT -

    Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening...

  • Aug 14, 2017
    Closes $3M private placement

    Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...

  • Aug 7, 2017
    - Procedure approved via the FDA's single-use expanded access program and was performed at a major U.S. hospital -

    Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...

Show 5102550100 per page

print email rss